Search
Results: 1
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers
Lieske H Schrijver, Antonis C Antoniou, Håkan Olsson, Thea M Mooij, Marie-José Roos-Blom, Leyla Azarang, Julian Adlard, Munaza Ahmed, Daniel Barrowdale, Rosemarie Davidson, Alan Donaldson, Ros Eeles, D Gareth Evans, Debra Frost, Alex Henderson, Louise Izatt, Kai-Ren Ong, Valérie Bonadona, Isabelle Coupier, Laurence Faivre, Jean-Pierre Fricker, Paul Gesta, Klaartje van Engelen, Agnes Jager, Fred H Menko, Marian JE Mourits, Christian F Singer, Yen Y Tan, Lenka Foretova, Marie Navratilova, Rita K Schmutzler, Carolina Ellberg, Anne-Marie Gerdes, Trinidad Caldes, Jacques Simard, Edith Olah, Anna Jakubowska, Johanna Rantala, Ana Osorio, John L Hopper, Kelly-Anne Phillips, Roger L Milne, Mary Beth Terry, Catherine Noguès, Christoph Engel, Karin Kast, David E Goldgar, Flora E van Leeuwen, Douglas F Easton, Nadine Andrieu, Matti A Rookus, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study Epidemiological Study of Familial Breast Cancer
Apr 21, 2021
BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in the general population are well...
Epidemiological Study of Familial Breast Cancer Gene Etude Prospective Sein Ovaire Sein Hereditary Breast and Ovarian Cancer Research Group Netherlands and International BRCA1/2 Carrier Cohort Study Humans Ovarian Neoplasms Genetic Predisposition to Disease Contraceptives Oral BRCA1 Protein BRCA2 Protein Proportional Hazards Models Retrospective Studies Cohort Studies Follow-Up Studies Mutation Adult Middle Aged Europe Female